Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells

• Published in: Biomaterials Vol. 26; no. 34; pp. 6941 - 6949
• Main Authors: von Knoch, Fabian, Jaquiery, Claude, Kowalsky, Marc, Schaeren, Stefan, Alabre, Claude, Martin, Ivan, Rubash, Harry E., Shanbhag, Arun S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-12-2005
• Subjects: Alendronate; Bisphosphonates; Bone Marrow Cells - cytology; Bone Marrow Cells - drug effects; Bone Marrow Cells - physiology; Bone morphogenetic protein; Cell Differentiation - drug effects; Cell Differentiation - physiology; Cell Proliferation - drug effects; Cells, Cultured; Diphosphonates - pharmacology; Human bone marrow stromal cells; Humans; Osteoblasts - cytology; Osteoblasts - drug effects; Osteoblasts - physiology; Osteogenesis - drug effects; Osteogenesis - physiology; Risedronate; Stromal Cells - cytology; Stromal Cells - drug effects; Stromal Cells - physiology; Total joint replacements; Zoledronate; Risedronate; Bone morphogenetic protein; Alendronate; Total joint replacements; Zoledronate; Bisphosphonates; Human bone marrow stromal cells
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2005.04.059

Bisphosphonates are well known potent inhibitors of osteoclast activity and are widely used to treat metabolic bone diseases. Recent evidence from in vitro and in vivo studies indicates that bisphosphonates may additionally promote osteoblastic bone formation. In this study, we evaluated the effects of three FDA-approved and clinically utilized bisphosphonates, on the proliferation and osteogenic differentiation of human bone marrow stromal cells (BMSC).
BMSC were obtained from patients undergoing primary total hip arthroplasty for end-stage degenerative joint disease. Cells were treated with or without a bisphosphonate (alendronate, risedronate, or zoledronate) and analyzed over 21 days of culture. Cell proliferation was determined by direct cell counting. Osteogenic differentiation of BMSC was assessed with alkaline phosphatase bioassay and gene expression analyses using conventional RT-PCR as well as real-time quantitative RT-PCR.
All bisphosphonates tested enhanced the proliferation of BMSC after 7 and 14 days of culture. Steady-state mRNA levels of key genes involved in osteogenic differentiation such as bone morphogenetic protein-2 (BMP-2), bone sialoprotein-II, core-binding factor alpha subunit 1 (cbfa1) and type 1 collagen, were generally increased by bisphosphonate treatment in a type- and time-dependent manner. Gene expression levels varied among the different donors. Enhancement of osteogenic differentiation was most pronounced after 14 days of culture, particularly following zoledronate treatment (
p
<
0.05
for BMP-2).
In conclusion, using a clinically relevant in vitro model we have demonstrated that bisphosphonates enhance proliferation of BMSC and initiate osteoblastic differentiation. When administered around joint replacements, bisphosphonates may potentially compensate for the deleterious effects of particulate wear debris at the bone–implant interface, by encouraging increased numbers of cells committed to the osteoblastic phenotype, and thus improve the longevity of joint replacements.